Hyperspectral Imaging for Prediction of Preeclampsia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorHeidelberg University

About this trial

Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia.

Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia.

The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.

Eligibility criteria

Qualifiers

singleton pregnancies

age ≥ 18 years

patient's ability to provide consent

written informed consent

Disqualifiers

lack of consent

language barrier

severe fetal chromosomal/genetic/structural anomalies known at study enrollment

smoking in the last two hours before measurement

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,430 Participants
are grouped into 2 trial groups

Sponsors and collaborators